Adeline A Lau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4543213/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Endoâ€lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?. Journal of Neurochemistry, 2017, 140, 703-717.	2.1	112
2	Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Human Molecular Genetics, 2007, 16, 2693-2702.	1.4	108
3	Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice. Behavioural Brain Research, 2008, 191, 130-136.	1.2	68
4	Reduction in open field activity in the absence of memory deficits in the AppNLâ^'Gâ''F knock-in mouse model of Alzheimer's disease. Behavioural Brain Research, 2018, 336, 177-181.	1.2	50
5	In vitro characterization of genetically modified embryonic stem cells as a therapy for murine mucopolysaccharidosis type IIIA. Molecular Genetics and Metabolism, 2004, 81, 86-95.	0.5	43
6	A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome. Human Gene Therapy, 2016, 27, 363-375.	1.4	37
7	Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice. Experimental Neurology, 2010, 225, 445-454.	2.0	30
8	SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors. Molecular Genetics and Metabolism, 2010, 100, 168-175.	0.5	25
9	A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA. Rapid Communications in Mass Spectrometry, 2014, 28, 933-938.	0.7	25
10	Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene, 2012, 491, 53-57.	1.0	22
11	AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains. Molecular Therapy - Methods and Clinical Development, 2020, 17, 174-187.	1.8	21
12	Neonatal Bone Marrow Transplantation in MPS IIIA Mice. JIMD Reports, 2012, 8, 121-132.	0.7	20
13	MPSâ€IIIA mice acquire autistic behaviours with age. Journal of Inherited Metabolic Disease, 2018, 41, 669-677.	1.7	11
14	Lysosomal Dysregulation in the Murine App Model of Alzheimer's Disease. Neuroscience, 2020, 429, 143-155.	1.1	11
15	Synthetic Disaccharide Standards Enable Quantitative Analysis of Stored Heparan Sulfate in MPS IIIA Murine Brain Regions. ACS Chemical Neuroscience, 2019, 10, 3847-3858.	1.7	10
16	A novel conditional <i>Sgsh</i> knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome. Journal of Inherited Metabolic Disease, 2017, 40, 715-724.	1.7	9
17	Lysosomal gene Hexb displays haploinsufficiency in a knock-in mouse model of Alzheimer's disease. IBRO Neuroscience Reports, 2022, 12, 131-141.	0.7	9
18	Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration. Journal of Molecular Medicine, 2017, 95, 1043-1052.	1.7	8

Adeline A Lau

#	Article	IF	CITATIONS
19	Variables influencing fluorimetric N-sulfoglucosamine sulfohydrolase (SCSH) activity measurement in brain homogenates. Molecular Genetics and Metabolism Reports, 2015, 5, 60-62.	0.4	6
20	MUCOPOLYSACCHARIDOSIS II (MPS II) IN A FREE-LIVING KAKA (NESTOR MERIDIONALIS) IN NEW ZEALAND. Journal of Wildlife Diseases, 2021, 57, 884-890.	0.3	2
21	Directed Differentiation and Characterization of Genetically Modified Embryonic Stem Cells for Therapy. , 2006, 329, 471-484.		1
22	Canine adenoviral vector-mediated gene transfer to the guinea pig brain. Gene Reports, 2019, 16, 100432.	0.4	1
23	Intracerebral gene therapy for mucopolysaccharidosis type IIIB syndrome. Lancet Neurology, The, 2017, 16, 681-682.	4.9	0